Skip to main content

Drug Interactions between agalsidase beta and migalastat

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

agalsidase beta migALAstat

Applies to: agalsidase beta and migalastat

Using agalsidase beta together with migALAstat is generally not recommended. Combining these medications may significantly increase the blood levels of agalsidase beta and increase its side effects. In addition, these medications are not intended to be used together for the treatment of Fabry disease. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Moderate

migALAstat food

Applies to: migalastat

Food reduces the absorption of migALAstat into the bloodstream, which may make the medication less effective in treating your condition. You should avoid eating for at least 2 hours before and 2 hours after taking migALAstat. Clear liquids may be consumed during this 4 hour period when you cannot eat.

Switch to professional interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Agents for fabry disease

Therapeutic duplication

The recommended maximum number of medicines in the 'agents for Fabry disease' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'agents for Fabry disease' category:

  • agalsidase beta
  • migalastat

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer